{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:57:46Z","timestamp":1791262666268,"version":"4.1.0"},"reference-count":50,"publisher":"Cambridge University Press (CUP)","issue":"14","license":[{"start":{"date-parts":[[2010,10,20]],"date-time":"2010-10-20T00:00:00Z","timestamp":1287532800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parasitology"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>For over fifty years, human African trypanosomiasis (HAT, sleeping sickness) has been treated with suramin, pentamidine and the very toxic organo-arsenical melarsoprol that was the only drug available for effective treatment of the second stage of the disease. Recently there have been significant efforts using molecular and biochemical approaches to drug design, including high-throughput screening, but the number of lead compounds with promising activity against<jats:italic>T. brucei<\/jats:italic>spp. and an acceptable toxicity index has remained astonishingly small. Clinical research continues to be difficult due to the economic constraints and the complexity of trials on a low prevalence disease in remote and impoverished African regions. Despite those limitations the situation for the patients is improving thanks to the combination of a number of critical factors. By the late 1990s the disease had reached epidemic levels that triggered political support. WHO would sign a donation agreement with the manufacturers for all drugs to treat HAT. A result of this agreement was that eflornithine which is much safer than melarsoprol became available and widely used by non-governmental organizations. The<jats:sc>Impamel<\/jats:sc>I and II programmes demonstrated that against all odds the conduct of clinical trials on HAT was feasible. This allowed the initiation of trials on combination therapies which eventually resulted in the nifurtimox-eflornithine combination treatment (NECT). This combination is currently being introduced as first line treatment, and there is even the prospect of having a new compound, fexinidazole, in the development pipeline. This review summarizes the key information about the existing drugs and gives a comprehensive summary about the recent and currently ongoing efforts towards new drugs.<\/jats:p>","DOI":"10.1017\/s0031182010001137","type":"journal-article","created":{"date-parts":[[2010,10,20]],"date-time":"2010-10-20T13:46:58Z","timestamp":1287582418000},"page":"1987-1994","source":"Crossref","is-referenced-by-count":93,"title":["Chemotherapy against human African trypanosomiasis: Is there a road to success?"],"prefix":"10.1017","volume":"137","author":[{"given":"CHRISTIAN","family":"BURRI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2010,10,20]]},"reference":[{"key":"S0031182010001137_ref50","volume-title":"Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis","year":"2007"},{"key":"S0031182010001137_ref49","first-page":"71","article-title":"Human African trypanosomiasis (sleeping sickness): epidemiological update","volume":"8","year":"2006","journal-title":"Weekly Epidemiological Report"},{"key":"S0031182010001137_ref46","first-page":"711","volume-title":"The African Trypanosomiases","author":"Waddy","year":"1970"},{"key":"S0031182010001137_ref45","doi-asserted-by":"publisher","DOI":"10.1007\/978-2-8178-0857-4_15"},{"key":"S0031182010001137_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2007.06.008"},{"key":"S0031182010001137_ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39485.592674.BE"},{"key":"S0031182010001137_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61117-X"},{"key":"S0031182010001137_ref37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0010039"},{"key":"S0031182010001137_ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0759-7"},{"key":"S0031182010001137_ref32","unstructured":"M\u00e9decins Sans Fronti\u00e8res (2007). Clinical Guidelines. http:\/\/www.refbooks.msf_docs\/en\/Clinical_Guide\/CG_en.pdf (Accessed 29 July 2010)."},{"key":"S0031182010001137_ref27","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1128\/AAC.41.9.1922","article-title":"Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine","volume":"41","author":"Iten","year":"1997","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"S0031182010001137_ref26","unstructured":"IFPMA and International Federation of Pharmaceutical Manufacturers & Associations (2008). Health Partnerships for the Developing World -Sanofi-Aventis Sleeping Sickness Program. Vol. 2008."},{"key":"S0031182010001137_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/0001-706X(93)90090-X"},{"key":"S0031182010001137_ref23","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1996.55.586"},{"key":"S0031182010001137_ref21","unstructured":"DNDi (2010). NECT \u2013 Nifurtimox-Eflornithine: Co-Administration (HAT). http:\/\/www.dndi.org\/portfolio\/nect.html (Accessed 24 June 2010)"},{"key":"S0031182010001137_ref20","article-title":"NECT added to WHO essential medicines list as combination treatment against sleeping sickness","year":"2009","journal-title":"DNDi Press Release"},{"key":"S0031182010001137_ref19","article-title":"Fexinidazole progresses into clinical development","volume":"17","year":"2008","journal-title":"DNDi Newsletter"},{"key":"S0031182010001137_ref18","article-title":"NECT: Next steps","volume":"17","year":"2008","journal-title":"DNDi Newsletter"},{"key":"S0031182010001137_ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000064"},{"key":"S0031182010001137_ref16","doi-asserted-by":"publisher","DOI":"10.1086\/432576"},{"key":"S0031182010001137_ref15","doi-asserted-by":"publisher","DOI":"10.1086\/522983"},{"key":"S0031182010001137_ref14","doi-asserted-by":"publisher","DOI":"10.1079\/9780851994758.0403"},{"key":"S0031182010001137_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02141-3"},{"key":"S0031182010001137_ref11","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for treatment of human African trypanosomiasis","volume":"90","author":"Burri","year":"2003","journal-title":"Parasitology Research"},{"key":"S0031182010001137_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(91)90364-5"},{"key":"S0031182010001137_ref9","unstructured":"Bronner U. (1994). Pharmacokinetics of pentamidine. Focus on treatment of Trypanosoma gambiense sleeping sickness. PhD Thesis, Karolinska Institute, Stockholm."},{"key":"S0031182010001137_ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707354"},{"key":"S0031182010001137_ref4","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.05.028399"},{"key":"S0031182010001137_ref2","unstructured":"Anonymous (2009). Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole. ClinicalTrials.gov (Clinical Trials Registry) http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00982904?term=NCT00982904&rank=1 (Accessed 24 June 2010)."},{"key":"S0031182010001137_ref43","doi-asserted-by":"publisher","DOI":"10.1086\/429929"},{"key":"S0031182010001137_ref47","article-title":"Epidemiology and control of African trypanosomiasis","volume":"739","year":"1986","journal-title":"WHO Technical Report Series"},{"key":"S0031182010001137_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.08.033"},{"key":"S0031182010001137_ref25","first-page":"160","volume-title":"Handbook of Drugs for Tropical Parasitic infections","author":"Gustafsson","year":"1987"},{"key":"S0031182010001137_ref44","unstructured":"Seixas J. (2004). Investigations on the encephalopathic syndrome during melarsoprol treatment of human African trypanosomiasis. PhD Thesis, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa."},{"key":"S0031182010001137_ref6","unstructured":"Bayer (2002). Bayer sustainable development report 2004. Vol. 2008. http:\/\/www.bayer.com\/en\/sustainable_development_report_2004.pdfx (Accessed 29 July 2010)."},{"key":"S0031182010001137_ref28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00050-08"},{"key":"S0031182010001137_ref29","first-page":"69","volume-title":"30th Meeting of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC)","author":"Kansiime","year":"2009"},{"key":"S0031182010001137_ref12","first-page":"1307","volume-title":"Manson's Tropical Diseases","author":"Burri","year":"2008"},{"key":"S0031182010001137_ref39","doi-asserted-by":"publisher","DOI":"10.1086\/522982"},{"key":"S0031182010001137_ref34","first-page":"1284","article-title":"Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial","volume":"78","author":"Pepin","year":"2000","journal-title":"Bulletin of the World Health Organization"},{"key":"S0031182010001137_ref48","volume-title":"Control and surveillance of African trypanosomiasis","year":"1998"},{"key":"S0031182010001137_ref3","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.031955"},{"key":"S0031182010001137_ref36","unstructured":"Pohlig G. , Bernhard S. , Blum J. , Burri C. , Mpanya Kabeya A. , Fina Lubaki J.-P. , Mpoo Mpoto A. , Fungula Munungu B. , Kambau Manesa Deo G. , Nsele Mutantu P. , Mbo Kuikumbi F. , Fukinsia Mintwo A. , Kayeye Munungi A. , Dala A. , Macharia S. , Miaka Mia Bilenge C. , Kande Betu Ku Mesu V. , Ramon Franco J. , Dieyi Dituvanga N. and Olson C. (2008). Phase 3 trial of pafuramidine maleate (DB289), a novel, oral drug, for treatment of first stage sleeping sickness: Safety and Efficacy. In 57th Meeting of the American Society of Tropical Medicine and Hygiene pp. Abstract No. 542. New Orleans."},{"key":"S0031182010001137_ref30","first-page":"70","volume-title":"30th Meeting of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC)","author":"Kuepfer","year":"2009"},{"key":"S0031182010001137_ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000225"},{"key":"S0031182010001137_ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2007.01948.x"},{"key":"S0031182010001137_ref7","doi-asserted-by":"publisher","DOI":"10.1086\/510534"},{"key":"S0031182010001137_ref1","volume-title":"Arzneimittel-Kompendium der Schweiz","author":"Dokumed","year":"2008"},{"key":"S0031182010001137_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(92)90298-Q"},{"key":"S0031182010001137_ref42","first-page":"738","article-title":"Control of human African trypanosomiasis in the Quicama focus, Angola","volume":"80","author":"Ruiz","year":"2002","journal-title":"Bulletin of the World Health Organization"}],"container-title":["Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0031182010001137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T02:26:05Z","timestamp":1592015165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0031182010001137\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,20]]},"references-count":50,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0031182010001137"],"URL":"https:\/\/doi.org\/10.1017\/s0031182010001137","relation":{},"ISSN":["0031-1820","1469-8161"],"issn-type":[{"value":"0031-1820","type":"print"},{"value":"1469-8161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,20]]}}}